EIF2AK2 and breast cancer: This trend is also evident in OncoDB (https://oncodb.org/index.html (accessed on 4 December 2022)), where the 12-year survival rate for breast cancer patients with low PKR expression is approximately 50%, whereas the 12-year survival rate for patients with high PKR expression is approximately 30%.